Long Term Follow-up of Cardiac Arrest Survivors Exposed to Ultra-rapid Cooling
Key facts
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Where
- France2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 12 people, planned
- Started
- 11 Jun 2025
- Expected to end
- Dec 2031
- Type of study
- Observational
- Treatments tested
- Short Form Health Survey (SF-36)
- Modified Rankin Score (mRS)
- Activity of Daily Living (ADL) questionnaire
- New York Heart Association (NYHA) Classification
- St George's Respiratory Questionnaire (SGRQ)
- Record updated
- 24 March 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Age of 18 years and over
- Cardiac arrest patient included in and alive at the end of the OverCool clinical investigation (28 days after the cardiac arrest)
- Non-opposition from the patient or the trusted person or the close relative or parent obtained within 3 months after the end of the OverCool study
Who cannot take part
- Follow-up refusal from patient of trusted person or the close relative or parent
- Having being included in the OverCool clinical investigation but not submitted to the Vent2Cool procedure
- Impossibility to reach the patient or the trusted person or the close relative or parent
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Less than 10% of patients eliciting out-of-hospital cardiac arrest (OHCA) survive, although 30% can be resuscitated by Emergency services before admission in Intensive Care Units (ICU). The majority succumb to Post-Cardiac Arrest Syndrome (PCAS). PCAS is associated with high mortality (60-70%) and morbidity.
Read full original descriptionShow less
One proposed method of preventing the neurological and cardiac consequences of PCAS is to lower the body temperature to 33°C as quickly as possible. This approach is known as therapeutic hypothermia or Targeted Temperature Management (TTM). The Vent2Cool system, developed by Orixha, is a novel approach that enables the rapid induction of therapeutic hypothermia by using hypothermic Total Liquid Ventilation (TLV) to reach a protective temperature of 33°C within minutes.
The OverCool feasibility study, which started in April 2025, is designed to validate the clinical performance and safety of an ultra-rapid cooling approach combining ultra-rapid hypothermia induction using the Vent2Cool system, and maintenance and rewarming using the ArcticSun system.
The AfterCool study aims to evaluate long-term outcomes during a five-year follow-up of cardiac arrest survivors who were treated with ultrarapid cooling in the OverCool study.
The group in the trial
- Resuscitated OverCool clinical investigation participants alive at 28 days after cardiac arrest
Patients who were resuscitated after cardiac arrest, treated with ultrarapid cooling as part of the OverCool clinical investigation and survived until the end of the investigation (28 days after cardiac arrest and subsequent Vent2Cool treatment).
Treatment: Short Form Health Survey (SF-36), Modified Rankin Score (mRS), Activity of Daily Living (ADL) questionnaire, New York Heart Association (NYHA) Classification, and St George's Respiratory Questionnaire (SGRQ)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Long Term Follow-up of Cardiac Arrest Survivors Exposed to Ultra-rapid Cooling, a Prospective Non-interventional Cohort
- Record updated
- 24 March 2026